Closed consultation on a proposed pilot approach to prioritize certain generic drug submissions involving domestic manufacturing within the review queue
Current status: Closed
This consultation ran from July 15, 2026 to September 12, 2026.
Health Canada sought feedback on a proposed pilot approach to prioritize certain generic drug submissions involving domestic manufacturing within the regulatory review queue. Stakeholders were invited to provide input on the proposed pilot, including its scope, eligibility criteria and attestation approach.
The proposed pilot approach to prioritize certain generic drug submissions involving domestic manufacturing within the review queue notice provided additional information about the proposed pilot.
Feedback received through the consultation will be used to refine the proposed approach and inform the design and implementation of the pilot.
Who was the focus of this consultation
We engaged with:
- Academia
- Health system partners
- Health care professionals
- Interested members of the public
- Patient Involvement organizations
- Industry and industry associations (human and veterinary)
Key questions for discussion
Through this consultation, Health Canada sought feedback on:
- a targeted, time-limited pilot to prioritize certain generic drug submissions involving domestic manufacturing with the regulatory review queue
Contact us
Health Canada
150 Tunney's Pasture Driveway
Ottawa, Ontario K1A 0K9
Address locator: 302B
Email: hpfb.engagement-mobilisation.dgpsa@hc-sc.gc.ca
From: Health Canada